Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.

[1]  J. Gallagher,et al.  Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. , 2005, The Journal of clinical endocrinology and metabolism.

[2]  J. Reginster,et al.  Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. , 2005, The Journal of clinical endocrinology and metabolism.

[3]  L. Quarles,et al.  A Novel Cation‐Sensing Mechanism in Osteoblasts Is a Molecular Target for Strontium , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  T. Spector,et al.  Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.

[5]  J. Reginster,et al.  Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis , 2003, Osteoporosis International.

[6]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[7]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[8]  J. Reginster,et al.  The use of different dual X-ray absorptiometry brands in a multicenter clinical trial: consequences and limits. , 1999, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[9]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[10]  R. Eastell.  Treatment of postmenopausal osteoporosis. , 1998, The New England journal of medicine.

[11]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[12]  A. Parfitt,et al.  Theoretical perspective: A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates , 1996 .

[13]  P. Marie,et al.  An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen‐deficient rats , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  L J Donaldson,et al.  Incidence of fractures in a geographically defined population. , 1990, Journal of epidemiology and community health.

[15]  J. Reginster,et al.  Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. , 2002, The Journal of clinical endocrinology and metabolism.

[16]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.